How to Value a GI Practice with an Ambulatory Surgery Center

Gastroenterology practices with integrated ambulatory surgery centers are among the most valuable physician-owned assets in healthcare. I've worked on dozens of GI/ASC transactions, and the valuation range is enormous — from 6x EBITDA for a poorly optimized single-location practice to 16x+ for a multi-site platform with high procedure volumes, in-house anesthesia, and strong pathology capture. The spread between a mediocre deal and a great one can be tens of millions of dollars.

What makes GI/ASC valuation unique is that you're not valuing one business — you're valuing two interconnected revenue streams that amplify each other. The clinic generates the patients. The ASC generates the procedures. And the ancillary services — anesthesia, pathology, infusion — create additional margin layers that sophisticated buyers know how to price. Let me break down how each piece gets valued.

The Combined Entity: Why 10-16x EBITDA Is Real

A standalone GI practice without an ASC might trade at 5-8x EBITDA — respectable, but not exceptional. A standalone ASC in a competitive market trades at 7-10x. But a GI practice that owns and operates its own endoscopy center creates a vertically integrated model that PE buyers value at 10-16x combined EBITDA. The premium exists because the integrated model controls the entire patient journey from referral through procedure through pathology, capturing margin at every step.

The PE interest in GI is not speculative. US Digestive Health (backed by Amulet Capital), GI Alliance (backed by Apollo), Gastro Health (backed by Omers), and PE GI Solutions have collectively spent billions acquiring GI practices since 2019. The thesis is straightforward: colonoscopy volumes are growing due to expanded screening guidelines (now starting at age 45), the procedures are high-margin and predictable, and consolidation creates meaningful operational synergies.

Where your practice falls within the 10-16x range depends on several factors I'll detail below. But the most important number in any GI/ASC valuation is combined facility EBITDA — the total earnings of both the practice and the ASC after normalizing physician compensation to market rates.

Endoscopy Center Economics: Procedure Volume Per Room Per Day

The single most important operational metric in an endoscopy ASC is procedures per room per day. This number tells a buyer everything about your center's efficiency, staffing model, and growth capacity.

Industry benchmarks look like this:

• Below average: 8-10 procedures per room per day. Indicates scheduling inefficiency, slow turnover times, or anesthesia bottlenecks.
• Average: 12-15 procedures per room per day. Most well-run GI ASCs operate in this range.
• Top quartile: 16-20 procedures per room per day. Requires exceptional nursing workflow, propofol-based sedation (faster recovery), and tight scheduling.

A two-room endoscopy center running 14 procedures per room per day, five days a week, generates roughly 7,280 procedures annually. At an average reimbursement of $800-$1,200 per procedure (facility fee only), that's $5.8M-$8.7M in ASC revenue from just two rooms. The margins on a well-run endoscopy center are extraordinary — 45-65% EBITDA margins are common because the fixed cost base (rent, equipment, core staff) doesn't scale linearly with volume.

Buyers scrutinize procedure volume trends obsessively. A center showing 10%+ annual procedure growth commands premium multiples. Flat or declining volumes raise immediate red flags about physician productivity, referral patterns, or competitive dynamics. If your volumes dipped during COVID but have fully recovered and exceeded pre-pandemic levels, make sure your data clearly shows that trajectory.

The Anesthesia Model: A Hidden Value Driver

How your ASC handles anesthesia has a surprisingly large impact on valuation. There are three common models, and they produce very different economics.

CRNA-supervised (no anesthesiologist).The most profitable model. CRNAs cost $180K-$220K annually versus $400K+ for an anesthesiologist. In states that allow independent CRNA practice, this model can save $200K-$500K per year per facility. Buyers love this because it's scalable and the cost savings drop straight to EBITDA.

Anesthesiologist-directed. Higher cost but sometimes required by payer contracts or state regulations. The key question is whether the anesthesia group is employed or contracted. An employed anesthesia team gives the buyer more control; a contracted group creates a dependency that buyers will want to renegotiate.

Moderate sedation (no anesthesia provider). Some GI practices still use physician-administered moderate sedation for routine colonoscopies. This eliminates anesthesia costs entirely but limits procedure throughput (slower recovery times, physician time spent on sedation management) and increasingly puts you at a competitive disadvantage with patients who prefer propofol. Buyers generally view this as an upgrade opportunity, not a negative — switching to propofol/CRNA typically increases net revenue per procedure.

Pathology Capture: The Margin Layer Most Sellers Undervalue

Every colonoscopy that finds a polyp generates a pathology specimen. In a typical GI practice, 30-40% of screening colonoscopies result in polypectomy. The question is: who reads that pathology, and who captures the margin?

Practices that have an in-house pathology arrangement— either an employed pathologist, a joint venture with a pathology group, or a captive pathology lab — capture an additional $80-$150 per specimen in professional and technical fees. On 3,000 polypectomy specimens per year, that's $240K-$450K in incremental revenue at very high margins.

PE buyers are acutely aware of pathology economics. A practice with strong pathology capture demonstrates operational sophistication and creates an additional revenue stream that's directly tied to procedure volume. Practices that send all pathology to an outside reference lab are leaving money on the table — and buyers know that recapturing that pathology margin post-acquisition is one of the easiest value-creation levers available.

If you're 2-3 years from selling, establishing a pathology capture model is one of the highest-ROI moves you can make. The setup costs are modest relative to the revenue impact, and the additional EBITDA gets multiplied at 10-16x in a sale.

What Drives You Toward 16x (and What Keeps You at 10x)

Factors that push multiples higher:

• Multi-site operations. Three or more locations with an ASC signals a platform, not a practice. PE buyers pay 12-16x for platforms because they see a foundation for further roll-up acquisitions.
• Multiple physicians. Six or more gastroenterologists reduces key-person risk and provides scheduling flexibility. Single-physician practices rarely break 10x regardless of volume.
• Diversified payer mix. Heavy Medicare concentration (common in GI due to screening guidelines) is a risk factor. Practices with a balanced commercial/Medicare mix get premium pricing.
• Infusion center. Biologic infusions for IBD patients (Remicade, Entyvio, Stelara) are a high-margin ancillary that adds recurring revenue and differentiates the practice.

Factors that compress multiples:

• Physician age and retirement risk. If the founding physicians are 60+ and no succession plan exists, buyers will discount for transition risk.
• ASC lease vs. ownership. Owning the ASC real estate outright (or having a favorable long-term lease) is worth 1-2x turns of multiple versus a short-term or above-market lease.
• Regulatory exposure. ASCs operate under CMS Conditions for Coverage. Any survey deficiencies, billing compliance issues, or quality of earnings concerns will suppress multiples quickly.
• Single-site limitation. A one-location GI/ASC with four physicians is a good business but not a platform. Expect 8-11x rather than 12-16x.

Structuring the Deal: What to Expect

GI/ASC transactions almost never involve a clean 100% sale with the physicians walking away. The typical structure looks like this: PE buys 60-70% of the combined entity at the headline multiple, physicians retain 30-40% and continue practicing for 5-7 years, and there's a second liquidity event when the PE firm exits (usually at a higher multiple, giving physicians a "second bite of the apple").

The retained equity is not window dressing. In many GI platform deals, the second bite has been worth 50-100% of the first. Physicians who sold to GI Alliance in 2019 at 12x and participated in the 2022 recapitalization effectively realized 18-20x on their original EBITDA. Understanding the full economic picture — not just the upfront check — is critical when evaluating competing offers.

Employment agreements, non-competes, call coverage requirements, and governance rights all need careful negotiation. The headline multiple matters, but the terms can easily swing the total economics by 20-30%.

The Bottom Line

GI practices with integrated ASCs are among the most sought-after assets in healthcare private equity. The combination of growing procedure volumes, high margins, multiple ancillary revenue streams, and proven consolidation economics makes this one of the few medical specialties where 10-16x EBITDA is consistently achievable. But the spread within that range is enormous, and it's driven by operational metrics — procedure volume per room, anesthesia model, pathology capture, physician depth — that sellers can actively improve in the years before a transaction. If you're a GI practice owner thinking about an exit in the next 3-5 years, optimizing these operational levers now will directly translate to millions of additional dollars at close.